Overview Formosa Pharmaceuticals, a Taiwan-based biopharma company, has announced an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. for the commercialization of clobetasol propionate ophthalmic suspension. The collaboration aims to bring a potent topical corticosteroid therapy to patients suffering from ocular inflammation, expanding Formosa’s portfolio in ophthalmology and Samil’s international reach. About the Agreement The…